Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Finding Study of Selinexor and Talazoparib in Patients With Advanced Refractory Solid Tumors, Followed by Phase II Expansion Cohort Study in Patients With Advanced/ Metastatic Triple Negative Breast Cancers. (START)

NCT05035745 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT05035745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05035745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Finding Study of Selinexor and Talazoparib in Patients With Advanced Refractory Solid Tumors, Followed by Phase II Expansion Cohort Study in Patients With Advanced/ Metastatic Triple Negative Breast Cancers. (START)
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 1, 2021
Completion date
November 30, 2027
Enrollment
63 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced refractory solid tumors, advanced triple negative breast cancers, metastatic triple negative breast cancers